The exploding growth of antibody therapies is predicted to reach ~$300 billion of market in 2026. Over 600 bispecifics are currently being investigated at various stages and >80% of this in clinical trials are developed to treat broad range of cancers. Being a genomic disease, each cancer needs early and precise diagnosis followed by personalized treatment. Antibody theranostics are currently used for both diagnosis and treatment. This presentation is tailored to highlight critical factors and prudent choice of profiling assays from early to late stage for successful development of antibody based theranostics for cancer treatment.
Sathya Venkataramani, Director Pre-Pivotal Drug Product Technologies - Biologics, Amgen